Please assess the completion status of the following clinical trial:

Trial Title: An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetics taking metformin IR or XR greater than or equal to 850mg and less than or equal to 1500mg only for at least 8 weeks prior to screening~* A1c: 7.5-11% (at screening)~* BMI less than or equal to 45 kg/m2~Exclusion Criteria:~* Significant cardiovascular history~* Active liver disease, renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Saxagliptin
- 2 (Type: ACTIVE_COMPARATOR): Metformin Extended Release

Based on this trial design, predict the completion outcome and termination type (if applicable).